Claims for Patent: 12,551,491

Summary for Patent: 12,551,491

Title:	Dosage regimens for benzgalantamine
Abstract:	A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine or a method of effectively administering galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the methods including orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.
Inventor(s):	Michael McFadden, Denis G. Kay
Assignee:	Alpha Cognition Inc
Application Number:	US19/278,636
Patent Claims:	1. A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the method comprising orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks. 2. The method according to claim 1, further comprising administering a maintenance dosage of 10 mg benzgalantamine gluconate, twice daily, after the starting dosage has been administered for the minimum of four weeks. 3. The method according to claim 2, wherein the 10 mg of benzgalantamine gluconate is administered for at least four weeks. 4. The method according to claim 3, further comprising administering a maximum dosage of 15 mg benzgalantamine gluconate, twice daily after administering the 10 mg benzgalantamine gluconate. 5. The method according to claim 1, wherein a steady state of galantamine is achieved within one week. 6. The method according to claim 1, wherein the dosage form is a tablet. 7. The method according to claim 5, wherein the dosage form is a delayed release tablet. 8. The method according to claim 5, wherein the dosage form comprises calcium silicate. 9. The method according to claim 7, wherein the dosage form comprises at least one of colloidal silicon dioxide, mannitol, and methacrylic acid. 10. The method according to claim 6, wherein the delayed release tablet comprises an enteric coating comprising methacrylic acid. 11. The method according to claim 10, wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer. 12. A method of effectively administering galantamine to a subject in need of treatment for mild to moderate dementia of the Alzheimer's type, the method comprising orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks. 13. The method according to claim 12, further comprising administering a dosage of 10 mg benzgalantamine gluconate, twice daily, after the starting dosage has been administered for the minimum of four weeks. 14. The method according to claim 13, further comprising administering a maximum dosage of 15 mg benzgalantamine gluconate, twice daily. 15. The method according to claim 12, wherein a steady state of galantamine is achieved within one week. 16. The method according to claim 12, wherein the dosage form is a tablet. 17. The method according to claim 16, wherein the dosage form is a delayed release tablet. 18. The method according to claim 12, wherein the dosage form comprises calcium silicate. 19. The method according to claim 12, wherein the dosage form comprises at least one of colloidal silicon dioxide, mannitol, and methacrylic acid. 20. The method according to claim 17, wherein the delayed release tablet comprises an enteric coating comprising methacrylic acid. 21. The method according to claim 18, wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer.